No abstract

Loss-of-function Aspergillus nidulans CclA, a Bre2 ortholog involved in histone 3 lysine 4 methylation, activated the expression of cryptic secondary metabolite (SM) clusters in A. nidulans. One novel cluster generated monodictyphenone, emodin and emodin derivatives while a second encoded two anti-osteoporosis polyketides, F9775A and F9775B. Modification of the chromatin landscape in fungal SM clusters allows for a simple technological means to express silent fungal secondary metabolite gene clusters.Aspergilli are ubiquitous filamentous fungi whose members include human and plant pathogens and industrial fungi with tremendous medical, agricultural and biotechnological importance. Although demonstrating synteny along large tracks of their sequenced genomes, * Corresponding authors: phone: (323) 442-1670; fax: (323) 442-1390, clayw@usc.edu, phone: (608) 262-9795; fax: (608) (2) clusters 3 . Yet the expression of most SM clusters and their concomitant products remain veiled. Two approaches for activating otherwise silent clusters were recently described. One strategy, utilizing the knowledge that many SM clusters contain a pathway specific transcription factor, fused an inducible promoter to a cluster transcription factor leading to the production of hybrid polyketide-nonribosomal peptide metabolites, the cytotoxic aspyridones A (3) and B (4) 4 . A second approach, based on genomic mining of microarrays generated from mutants of the global regulator of secondary metabolism LaeA 5, 6, 7 , led to the identification of the anti-tumor compound terrequinone A (5) 8 . Efforts to uncover the regulatory role of LaeA revealed that some subtelomeric SM clusters were located in heterochromatic regions of the genome where suppression was relieved by deletion of a key histone deacetylase 9 . The importance of histone modifications in SM clusters was further reflected in the initiation and spread of histone H4 acetylation concurrent with transcriptional activation of the subtelomeric A. parasiticus aflatoxin (6) gene cluster 10 .A consideration of the accruing evidence linking chromatin modifications with SM cluster regulation led us to examine the hypothesis that additional chromatin modifying proteins were important in SM cluster regulation. In particular, we examined a member of the COMPASS (complex associated with Set1) complex for possible regulatory roles in SM silencing. The COMPASS complex is a conserved eukaryotic transcriptional effector both facilitating and repressing chromatin-mediated processes through methylation of lysine 4 of histone 3 (H3K4) 11,12 . While H3K4me2 and H3K4me3 are found predominantly on active loci 12 , the COMPASS complex also regulates homothallic mating silencing, ribosomal DNA silencing, telomere length, and subtelomeric gene expression in yeast [13][14][15] .A critical member of the COMPASS complex is the SPRY domain protein designated Bre2 in Saccharomyces cerevisiae 11 . Analysis of the A. nidulans genome revealed a putative ortholog, here named CclA. Extracts of cclA delet...

Deletion of cclA, a component of the COMPASS complex of Aspergillus nidulans, results in the production of monodictyphenone and emodin derivatives. Through a set of targeted deletions in a cclA deletion strain, we have identified the genes required for monodictyphenone and emodin analog biosynthesis. Identification of an intermediate, endocrocin, from an mdpH⌬ strain suggests that mdpH might encode a decarboxylase. Furthermore, by replacing the promoter of mdpA (a putative aflJ homolog) and mdpE (a putative aflR homolog) with the inducible alcA promoter, we have confirmed that MdpA functions as a coactivator. We propose a biosynthetic pathway for monodictyphenone and emodin derivatives based on bioinformatic analysis and characterization of biosynthetic intermediates.

Chiral block copolymers (BCPs*) comprising chiral entities were designed to fabricate helical architectures (i.e., twisted morphologies) from self-assembly. A new helical phase (H*) with P622 symmetry was discovered in the self-assembly of poly(styrene)-b-poly(l-lactide) (PS-PLLA) BCPs*. Hexagonally packed, interdigitated PLLA helical microdomains in a PS matrix were directly visualized by electron tomography. The phase diagram of the PS-PLLA BCPs* was also established. Phase transitions from the H* phase to the stable cylinder and gyroid phases were found after long-time annealing, suggesting that the H* is a long-lived metastable phase. In contrast to racemic poly(styrene)-b-poly(d,l-lactide) BCPs, chiral interaction significantly enhances the incompatibility between achiral PS and chiral PLLA blocks in the PS-PLLA BCPs* and can be estimated through the determination of the interaction parameter.

The sequencing of Aspergillus genomes has revealed that the products of a large number of secondary metabolism pathways have not yet been identified. This is probably because many secondary metabolite gene clusters are not expressed under normal laboratory culture conditions. It is, therefore, important to discover conditions or regulatory factors that can induce the expression of these genes. We report that the deletion of sumO, the gene that encodes the small ubiquitin-like protein SUMO in A. nidulans, caused a dramatic increase in the production of the secondary metabolite asperthecin and a decrease in the synthesis of austinol/ dehydroaustinol and sterigmatocystin. The overproduction of asperthecin in the sumO deletion mutant has allowed us, through a series of targeted deletions, to identify the genes required for asperthecin synthesis. The asperthecin biosynthesis genes are clustered and include genes encoding an iterative type I polyketide synthase, a hydrolase, and a monooxygenase. The identification of these genes allows us to propose a biosynthetic pathway for asperthecin.Secondary metabolites are a remarkably rich source of medically useful compounds. A survey of the literature on 1,500 secondary metabolites isolated and characterized between 1993 and 2001 revealed that over half of these compounds have antibacterial, antifungal, or antitumor activity (19). Fungal secondary metabolites, in particular, include a number of important compounds, such as penicillin, cephalosporin, the antihypercholesterolemic agent lovastatin and other statins, and immunosuppressants such as cyclosporine, as well as antifungals (reviewed in references 3, 13, 16, and 19). Other fungal secondary metabolites are important not for their benefits but rather for the problems they cause. For example, the carcinogenic toxins aflatoxin and sterigmatocystin are produced by members of the genus Aspergillus (see references 7, 28, and 29 and earlier references therein; reviewed additionally in references 1 and 26).The sequencing of fungal genomes has revealed several important things about fungal secondary metabolism. First, as was suspected from the results of previous work (13), the genes of pathways that produce particular secondary metabolites are often clustered together (10, 14, 18). Second, fungi have many more secondary metabolism pathways than was previously thought. Analyses of the A. nidulans genome, for example, indicate that A. nidulans has 50 clusters that are predicted to synthesize secondary metabolites (27 polyketides, 14 nonribosomal peptides, 6 fatty acids, 1 terpene, and 2 indole alkaloids) (3, 18). Our own genomic analyses suggest that this number may be a slight overestimate (because more than one polyketide synthase [PKS] and/or nonribosomal peptide synthetase may be involved in a single pathway), but clearly A. nidulans has the ability to synthesize many secondary metabolites. Only a limited number of secondary metabolites in A. nidulans have been identified (aspyridones A and B [from a single pathway], aspoqui...

No abstract

No abstract

No abstract